X

Trial Profile

A Phase 1 trial of IDP-023 in multiple sclerosis

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 19 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IDP 023 (Primary)
Indications Multiple sclerosis
Focus Adverse reactions

Most Recent Events

17 Dec 2024 According to an Indapta Therapeutics media release, company look forward to initiating our Phase 1 trial for multiple sclerosis in Q1 2025.
06 Aug 2024 According to an Indapta Therapeutics media release, company announced that the U.S. FDA has cleared the IND for this trial
23 May 2024 According to an Indapta Therapeutics media release, company plans to file IND for Phase 1 trial of IDP-023 in multiple sclerosis in mid-2024 with the U.S. Food and Drug Administration.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com